New Patient Information Leaflet published for women & girls taking Sodium Valproate (Epilim)
An updated Patient Information Leaflet has been published for women and girls that are taking Sodium Valproate (Epilim).
The Patient Information Leaflet has been updated to incorporate further research which has taken place on the potential impacts of the drug if prescribed in pregnancy. If a child is exposed to Sodium Valproate in utero, this can cause serious developmental disorders in 30-40% of cases; while in 10% of cases it can cause congenital malformations for the child.